SCIENTURE Secures Multiple Commercial GPO Agreements, Expanding U.S. Market Access for Arbli™ (losartan potassium) to more than 2500 Healthcare Institutions
Scienture Holdings (NASDAQ: SCNX) has secured multiple Group Purchasing Organization (GPO) agreements for Arbli™ (losartan potassium), expanding access to over 2,500 healthcare institutions, representing ~20% of the U.S. institutional market.
Arbli™ is the first FDA-approved ready-to-use oral suspension of losartan, targeting a $256M annual market with 71M prescriptions. The drug is approved for treating hypertension in patients over six years old, reducing stroke risk in hypertensive patients with left ventricular hypertrophy, and treating diabetic nephropathy in type 2 diabetes patients.
The product addresses unmet needs with its liquid formulation, eliminating compounding requirements while offering reduced dosing volume and room temperature storage stability. Arbli™ is protected by two USPTO patents listed in the FDA Orangebook.
Scienture Holdings (NASDAQ: SCNX) ha concluso diversi accordi con Organizzazioni di Acquisto di Gruppo (GPO) per Arbli™ (losartano potassico), estendendo l’accesso a oltre 2.500 istituzioni sanitarie, pari a circa il 20% del mercato istituzionale statunitense.
Arbli™ è la prima sospensione orale pronta all’uso di losartano approvata dalla FDA, con un mercato annuo previsto di 256 milioni di dollari e 71 milioni di prescrizioni. Il farmaco è autorizzato per trattare l’ipertensione nei pazienti di età superiore ai sei anni, ridurre il rischio di ictus tra gli ipertesi con ipertrofia ventricolare sinistra e trattare la nefropatia diabetica nei pazienti con diabete di tipo 2.
Il prodotto risponde a bisogni non soddisfatti grazie alla formulazione liquida, eliminando la necessità di preparazioni complesse, offrendo un volume di dosaggio ridotto e una stabilità a temperatura ambiente. Arbli™ è protetto da due brevetti USPTO elencati nel FDA Orange Book.
Scienture Holdings (NASDAQ: SCNX) ha asegurado múltiples acuerdos con Organizaciones de Compras GPO para Arbli™ (losartán potásico), ampliando el acceso a más de 2.500 instituciones de atención médica, lo que representa aproximadamente el 20% del mercado institucional de EE. UU.
Arbli™ es la primera suspensión oral lista para usar de losartán aprobada por la FDA, orientada a un mercado anual de $256 millones con 71 millones de prescripciones. El fármaco está aprobado para tratar la hipertensión en pacientes mayores de seis años, reducir el riesgo de ictus en hipertensos con hipertrofia ventricular izquierda y tratar la nefropatía diabética en pacientes con diabetes tipo 2.
El producto cubre necesidades insatisfechas con su formulación líquida, eliminando la necesidad de reconstituciones, ofreciendo un volumen de dosis reducido y estabilidad a temperatura ambiente. Arbli™ está protegido por dos patentes de USPTO listadas en el FDA Orange Book.
Scienture Holdings (NASDAQ: SCNX)은 Arbli™(로사르탄 칼륨)에 대한 다수의 그룹 구매 조직(GPO) 계약을 체결하여 2,500개가 넘는 의료 기관에 접근성을 확대했으며 이는 미국 기관 시장의 약 20%를 차지합니다.
Arbli™는 사용 준비 완료 용액형 로사르탄의 FDA 승인 첫 사례로, 연간 시장 규모가 $256M이고 7,100만 건의 처방이 예상됩니다. 이 약은 6세 이상 고혈압 환자 치료, 좌심실 비대가 있는 고혈압 환자의 뇌졸중 위험 감소, 제2형 당뇘 환자의 당뇨망행병 치료에 승인되어 있습니다.
이 제품은 액상 제형으로 충족되지 못한 요구를 해결하며 조제 필요를 제거하고, 용량 부피를 줄이며 상온 보관 안정성을 제공합니다. Arbli™는 FDA Orange Book에 기재된 두 개의 USPTO 특허로 보호됩니다.
Scienture Holdings (NASDAQ: SCNX) a obtenu plusieurs accords avec des Organisations de Purchasing Group (GPO) pour Arbli™ (losartan potassique), élargissant l’accès à plus de 2 500 établissements de soins, soit environ 20 % du marché institutionnel américain.
Arbli™ est la première suspension orale prête à l’emploi de losartan approuvée par la FDA, visant un marché annuel de 256 millions de dollars et 71 millions de prescriptions. Le médicament est approuvé pour traiter l’hypertension chez les patients âgés de plus de six ans, réduire le risque d’AVC chez les hypertendus avec une hypertrophie ventriculaire gauche, et traiter la néphropathie diabétique chez les patients diabétiques de type 2.
Le produit répond à des besoins non satisfaits grâce à sa formulation liquide, éliminant les préparations à domicile, tout en offrant un volume de dosage réduit et une stabilité à température ambiante. Arbli™ est protégé par deux brevets USPTO inscrits dans l’Orange Book de la FDA.
Scienture Holdings (NASDAQ: SCNX) hat mehrere Vereinbarungen mit Group Purchasing Organizations (GPOs) für Arbli™ (Losartankalium) getroffen und damit den Zugang zu über 2.500 Gesundheitseinrichtungen erweitert, was ca. 20 % des institutionellen US-Markts entspricht.
Arbli™ ist die erste gebrauchsfertige orale Suspension von Losartan, die von der FDA zugelassen ist, und zielt auf einen jährlichen Markt von 256 Mio. USD mit 71 Mio. Verschreibungen ab. Das Medikament ist zugelassen zur Behandlung von Bluthochdruck bei Patienten über sechs Jahren, zur Reduzierung des Schlaganfallrisikos bei Hypertrophie des linken Ventrikels und zur Behandlung der diabetischen Nephropathie bei Typ-2-Diabetes.
Das Produkt spricht unerfüllte Bedürfnisse mit seiner flüssigen Formulierung an, eliminiert die Notwendigkeit für Ausschuss- oder Mischbereitschaft, bietet ein reduziertes Dosierungsvolumen und ist bei Raumtemperatur stabil. Arbli™ ist durch zwei USPTO-Patente geschützt, die im FDA Orange Book aufgeführt sind.
Scienture Holdings (NASDAQ: SCNX) أبرمت عدة اتفاقيات مع منظمات الشراء الجماعي (GPOs) لمنتج Arbli™ (لوبارتان بوتاسيوم)، مما وسع الوصول إلى أكثر من 2,500 مؤسسة صحية، وهو ما يمثل نحو 20% من السوق المؤسسي في الولايات المتحدة.
Arbli™ هي أول تعليق فموي جاهز للاستخدام من اللورساتان معتمد من FDA، تستهدف سوقاً سنوياً قدره 256 مليون دولار مع 71 مليون وصفة طبية. الدواء معتمد لعلاج ارتفاع ضغط الدم لدى المرضى الذين تزيد أعمارهم عن ست سنوات، وتقليل مخاطر السكتة الدماغية لدى مرضى ارتفاع ضغط الدم المصابين بتضخم البطين الأيسر، وعلاج الاعتلال الكلوي السكري لدى مرضى السكري من النوع 2.
يزوِّد المنتج احتياجات غير ملبَّاة من خلال صياغته السائلة، مما يلغي الحاجة إلى التحضير، ويقدم حجم جرعة مخفضاً كما أن له استقراراً في التخزين بدرجة حرارة الغرفة. Arbli™ محمي ببراءتين من USPTO مذكورتين في FDA Orange Book.
Scienture Holdings（纳斯达克：SCNX） 已就 Arbli™（洛萨坦钾盐） 与多个集团采购组织（GPO）签订协议，将覆盖范围扩展至 2,500 多家医疗机构，约占美国机构市场的 20%。
Arbli™ 是 FDA 批准的第一款可直接使用的洛萨坦口服悬液制剂，面向每年 2.56 亿美元 市场，预计有 7100 万处方。该药物已获批用于治疗六岁以上患者的高血压，降低左心室肥厚患者中风风险，并治疗2型糖尿病患者的糖尿病肾病。
该产品通过液体制剂满足未被满足的需求，消除了配制的需求，且给药体积更小，室温存储稳定。Arbli™ 受两项 USPTO 专利保护，列在 FDA Orange Book 中。
- Secured GPO agreements providing access to over 2,500 healthcare institutions (~20% of U.S. institutional market)
- First FDA-approved ready-to-use oral suspension in a $256M annual losartan market with 71M prescriptions
- Two USPTO patents provide market exclusivity protection
- Addresses unmet market need with unique liquid formulation advantages over existing solid forms
- Will face competition from established generic losartan tablets in the market
- Market penetration dependent on successful conversion of patients from existing oral solid forms
Insights
Scienture's GPO deals for Arbli potentially unlock access to 20% of institutional market in $256M losartan sector with first ready-to-use suspension.
Scienture's multiple commercial GPO agreements for Arbli™ represent a significant commercial milestone that could substantially accelerate market penetration. By securing access to over 2500 healthcare institutions – approximately 20% of the U.S. institutional market – Scienture has created a clear pathway for adoption across hospitals, long-term care facilities, and outpatient settings.
The strategic importance of these agreements stems from Arbli's unique position as the first FDA-approved ready-to-use losartan oral suspension. The U.S. losartan market is substantial at
GPO contracts are particularly valuable as they eliminate the need for individual institutional negotiations, creating a streamlined adoption pathway once the product is listed. Arbli's competitive advantages – consistent quality, dosing accuracy, reduced volume, and room-temperature storage stability – address significant limitations of compounded alternatives while meeting critical clinical needs.
The company's patent protection (two USPTO patents listed in the FDA Orange Book) provides additional commercial security. While revenue projections aren't specified, these agreements establish the foundational infrastructure needed for Arbli's commercial success by opening access to a significant portion of the institutional market, with plans to expand further through additional GPO partnerships and direct contracts.
Represents potential penetration into ~
U.S. losartan market totals
COMMACK, NY, Oct. 01, 2025 (GLOBE NEWSWIRE) -- SCIENTURE HOLDINGS, INC. (NASDAQ: SCNX), a holding company for existing and planned pharmaceutical operating companies focused on providing enhanced value to patients, physicians and caregivers through the development, commercialization, and distribution of novel specialty products that address unmet market needs, today announced that it has formalized multiple commercial group purchasing organization (GPO) agreements for ArbliTM (losartan potassium) Oral Suspension, 10 mg/mL, providing access to more than 2500 healthcare institutions, including hospitals, clinics, nursing homes, specialty pharmacies, long-term care facilities, and ambulatory centers, representing potential penetration into an estimated
“Securing these GPO agreements is a pivotal milestone for Scienture and for Arbli™,” commented Narasimhan Mani, President and co-CEO of Scienture. “By gaining access to more than 2500 healthcare institutions, we are positioning Arbli™ to reach the patients and providers who need it most. Looking ahead, we plan to further expand our GPO partnerships and direct contracts to deepen institutional market penetration nationwide. This strategy underscores our commitment to creating meaningful growth opportunities and long-term value for shareholders.”
ArbliTM is a novel proprietary formulation of losartan, a widely prescribed angiotensin receptor blocker (ARB) for hypertension. It is the first and only liquid formulation of losartan on the market that does not require compounding and has reduced dosing volume and long-term shelf life at room temperature storage. ArbliTM is FDA-approved for the treatment of hypertension in patients greater than six years old, for reducing the risk of stroke in patients with hypertension and left ventricular hypertrophy, and for treating diabetic nephropathy in certain patients with type 2 diabetes. By offering a safe, effective, and convenient liquid alternative, Arbli™ provides a tailored solution for patients who require or prefer a liquid formulation. As an FDA-approved product, Arbli™ provides consistent quality and dosing accuracy, addressing the risks and inconsistencies often associated with extemporaneously compounded losartan prescriptions. ArbliTM has two issued patents from the USPTO, which are also listed in the FDA Orangebook.
According to IQVIA data (MAT June 2025), the U.S. losartan market represents approximately
“GPO agreements often serve as a strategic gateway,” stated Shankar Hariharan, Executive Chairman and co-CEO of Scienture. “Once a product is listed on a contract, it becomes accessible to all member institutions, enabling adoption to scale rapidly without renegotiating individual agreements. These agreements highlight a significant opportunity for Arbli™ as the first FDA-approved, ready-to-use oral suspension.”
About ArbliTM
ArbliTM is the first and only oral liquid formulation of losartan approved by the U.S. FDA. Arbli™ comes in a 165 mL bottle as a peppermint flavored suspension that does not require refrigeration, and has been approved for a shelf life of 24 months from the date of manufacture when stored at room temperature.
INDICATION
ArbliTM is an angiotensin II receptor blocker (ARB) indicated for:
- Treatment of hypertension, to lower blood pressure in adults and children greater than 6 years old. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions.
- Reduction of the risk of stroke in patients with hypertension and left ventricular hypertrophy.
- Treatment of diabetic nephropathy with an elevated serum creatinine and proteinuria in patients with type 2 diabetes and a history of hypertension.
IMPORTANT SAFETY INFORMATION
- Do not take ArbliTM when pregnant. When pregnancy is detected, discontinue ArbliTM as soon as possible. Drugs that act directly on the renin-angiotensin system can cause injury and death to the developing fetus. ArbliTM can cause fetal harm when administered to a pregnant woman. Use of drugs that act on the renin-angiotensin system during the second and third trimesters of pregnancy reduces fetal renal function and increases fetal and neonatal morbidity and death.
- Do not co-administer ArbliTM with aliskiren in patients with diabetes. Avoid use of aliskiren with ArbliTM in patients with renal impairment (GFR <60 mL/min).
- Do not administer ArbliTM in patients with severe hepatic impairment. ArbliTM has not been studied in patients with severe hepatic impairment.
- The most common adverse reactions are (incidence ≥
2% and greater than placebo): dizziness, upper respiratory infection, nasal congestion, and back pain.
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088. You may also contact Scienture at 1-833-754-4917.
Please see the full Prescribing Information for complete product information. For more information, talk to your healthcare provider.
About Hypertension
Hypertension (high blood pressure) is a cardiovascular condition, when the pressure in the blood vessels is too high (140/90 mmHg or higher). According to the CDC, hypertension, or high blood pressure, affects nearly half of adults in the United States, or 119.9 million people. Hypertension is defined as a systolic blood pressure of 140 mmHg or higher, and diastolic blood pressure of 90 mmHg or higher. Hypertension is a risk factor for stroke and heart disease, which are leading causes of death in the U.S. Factors that increase the risk of having high blood pressure include: older age, genetics, being overweight or obese, not being physically active, high-salt diet and drinking too much alcohol. Hypertension is clinically diagnosed if, when blood pressure is measured on two different days, the systolic blood pressure readings on both days is ≥140 mmHg and/or the diastolic blood pressure readings on both days is ≥ 90 mmHg.
About Scienture Holdings, Inc.
SCIENTURE HOLDINGS, INC. (NASDAQ: “SCNX”), through its wholly owned subsidiary, Scienture, LLC, is a comprehensive pharmaceutical product company focused on providing enhanced value to patients, physicians and caregivers by offering novel specialty products to satisfy unmet market needs. Scienture, LLC is a branded, specialty pharmaceutical company consisting of a highly experienced team of industry professionals who are passionate about developing and bringing to market unique specialty products that provide enhanced value to patients and healthcare systems. The assets in development at Scienture are across therapeutics areas, indications and cater to different market segments and channels. For more information please visit: www.scientureholdings.com and www.scienture.com.
Cautionary Statements Regarding Forward-Looking Statements
This press release contains certain statements that may be deemed to be “forward-looking statements” within the federal securities laws, including the safe harbor provisions under the Private Securities Litigation Reform Act of 1995. Statements that are not historical are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements relate to future events or our future performance or future financial condition. These forward-looking statements are not historical facts, but rather are based on current expectations, estimates and projections about our company, our industry, our beliefs and our assumptions. Such forward-looking statements include, but are not limited to, statements regarding our or our management team’s expectations, hopes, beliefs, intentions or strategies regarding the future, including for the products we may launch, the success those products may have in the marketplace, and our strategies related to those products. In addition, any statements that refer to projections, forecasts or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking statements. In some cases, you can identify forward-looking statements by the following words: “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “ongoing,” “plan,” “potential,” “predict,” “project,” “should,” or the negative of these terms or other similar expressions, but the absence of these words does not mean that a statement is not forward-looking. Forward-looking statements are subject to a number of risks and uncertainties (some of which are beyond our control) that may cause actual results or performance to be materially different from those expressed or implied by such forward-looking statements. Accordingly, readers should not place undue reliance on any forward-looking statements. These risks include risks relating to agreements with third parties; our ability to raise funding in the future, as needed, and the terms of such funding, including potential dilution caused thereby; our ability to continue as a going concern; security interests under certain of our credit arrangements; our ability to maintain the listing of our common stock on the Nasdaq Capital Market; claims relating to alleged violations of intellectual property rights of others; the outcome of any current legal proceedings or future legal proceedings that may be instituted against us; unanticipated difficulties or expenditures relating to our business plan; and those risks detailed in our most recent Annual Report on Form 10-K and subsequent reports filed with the SEC.
Forward-looking statements speak only as of the date they are made. Scienture Holdings, Inc. undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise that occur after that date, except as otherwise provided by law.
Contact:
SCIENTURE HOLDINGS, INC.
20 Austin Blvd
Commack, NY 11725
Phone: (866) 468-6535
Email: IR@Scienture.com
FAQ
What is the market size for Scienture's (SCNX) Arbli losartan product?
How many healthcare institutions can access Scienture's (SCNX) Arbli through the new GPO agreements?
What are the approved indications for Scienture's (SCNX) Arbli?
What makes Scienture's (SCNX) Arbli different from other losartan products?
How is Scienture's (SCNX) Arbli protected from competition?
